A Study of Selinexor and Pembrolizumab for the Treatment of Bladder Cancer
Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma, Carcinoma, Transitional Cell Carcinoma, Pembrolizumab, Selinexor
Lead Scientist at UC Davis
- Mamta Parikh
Assistant Professor, Hematology and Oncology, School of Medicine. Authored (or co-authored) 25 research publications